PFIZER INC (PFE)

US7170811035 - Common Stock

26.36  +0.59 (+2.29%)

After market: 26.36 0 (0%)

PFIZER INC

NYSE:PFE (12/20/2024, 8:04:00 PM)

After market: 26.36 0 (0%)

26.36

+0.59 (+2.29%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%723.53%
Sales Q2Q%33.78%
CRS25.97
6 Month-4.97%
Overview
Earnings (Last)10-29 2024-10-29/bmo
Earnings (Next)01-28 2025-01-28/amc
Ins Owners0.02%
Inst Owners67.53%
Market Cap149.38B
Shares5.67B
PE10.22
Fwd PE9.02
Dividend Yield6.67%
Analysts72
Short Float %1.6%
Short Ratio2.09
IPO01-17 1944-01-17
Stock Screener Links
Screen Image

New York Stock Exchange, Inc. Stock Screener

Find more stocks on New York Stock Exchange, Inc.

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PFE Daily chart

Company Profile

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The company is headquartered in New York City, New York and currently employs 88,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Company Info

PFIZER INC

66 Hudson Boulevard East

New York City NEW YORK 10017

P: 12127332323

CEO: Albert Bourla

Employees: 88000

Website: https://www.pfizer.com/

PFE News

News Image21 hours ago - The Motley FoolThe Stock Market Is Historically Pricey: Here's How I'm Positioning My Portfolio for 2025

When things seem too good to be true on Wall Street, they usually are.

News Imagea day ago - The Motley FoolMy Top 10 Stocks to Buy for 2025
News Imagea day ago - The Business JournalsPfizer cost cutting leads to Tampa layoffs
News Imagea day ago - Market News VideoNotable Friday Option Activity: RYTM, PFE, PEP
News Image2 days ago - Pfizer Inc.U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
News Image2 days ago - EIN PresswireNeuropathic Pain Market Set to Witness Significant Growth by 2024-2031 | Pfizer, Inc., Johnson & Johnson Services

Global Neuropathic Pain Market is estimated to valued at US$ 7.56 Billion in 2023 and expected to exhibit a CAGR of 6.2% during the forecast period 2023-2030

PFE Twits

Here you can normally see the latest stock twits on PFE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example